Sanofi says it has reached an agreement with Dren Bio that would see it take control of autoimmune disease treatment DR-0201, a bispecific antibody-based myeloid cell engager with the potential to ...

Dren Bauta returned to school in February after missing nine months. He credits his determination to rejoin his football team as a major motivation. MONTVALE – Dren Bauta couldn’t swallow blueberries.

ADEL-Y01, a monoclonal antibody targeting tau protein, is in Phase I trials for Alzheimer's disease, developed by ADEL and licensed to Sanofi. The ADEL-Sanofi agreement is valued at over $1.04 billion ...

Dec 15 (Reuters) - Private biotech company Dren Bio has entered into a strategic collaboration with French drugmaker Sanofi (SASY.PA), opens new tab to develop therapies for autoimmune diseases in a ...

– New collaboration builds on Sanofi’s prior acquisition of DR-0201 and further leverages Dren Bio’s proprietary Targeted Myeloid Engager and Phagocytosis Platform to discover first-in-class ...

Under the agreement, Dren Bio will receive an upfront payment of $100 million and could earn up to $1.7 billion in additional development, regulatory, and commercial milestone payments. The deal ...

Dren Bio, a privately held, clinical-stage biotechnology company developing therapeutics for cancer, autoimmune, and other serious diseases, announced today that it received the 2025 Prix Galien USA ...

İSTANBUL'da özel bir hastanede sezaryenle doğum yapan Ebru Arslan, 7 ay sonra şiddetli ağrılar üzerine tekrar muayene gitti. Doktorlar, Arslan'ın karnında ip unutulduğunu söyledi. Ancak Arslan, farklı ...